Arax Advisory Partners’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,000
| Closed | -$701 | – | 3046 |
|
|
2025
Q1 | $701 | Hold |
1,000
| – | – | ﹤0.01% | 2449 |
|
|
2024
Q4 | $1.2K | Hold |
1,000
| – | – | ﹤0.01% | 2130 |
|
|
2024
Q3 | $1.71K | Hold |
1,000
| – | – | ﹤0.01% | 2110 |
|
|
2024
Q2 | $1.17K | Hold |
1,000
| – | – | ﹤0.01% | 2121 |
|
|
2024
Q1 | $990 | Hold |
1,000
| – | – | ﹤0.01% | 1155 |
|
|
2023
Q4 | $3.92K | Hold |
1,000
| – | – | ﹤0.01% | 927 |
|
|
2023
Q3 | $5.75K | Hold |
1,000
| – | – | ﹤0.01% | 847 |
|
|
2023
Q2 | $8.1K | Hold |
1,000
| – | – | ﹤0.01% | 760 |
|
|
2023
Q1 | $7K | Hold |
1,000
| – | – | ﹤0.01% | 765 |
|
|
2022
Q4 | $7.06K | Hold |
1,000
| – | – | ﹤0.01% | 707 |
|
|
2022
Q3 | $15K | Hold |
1,000
| – | – | ﹤0.01% | 607 |
|
|
2022
Q2 | $10K | Hold |
1,000
| – | – | ﹤0.01% | 652 |
|
|
2022
Q1 | $14K | Hold |
1,000
| – | – | ﹤0.01% | 612 |
|
|
2021
Q4 | $52K | Hold |
1,000
| – | – | 0.01% | 449 |
|
|
2021
Q3 | $58K | Buy |
1,000
+300
| +43% | +$19.6K | 0.01% | 430 |
|
|
2021
Q2 | $56K | Buy |
+700
| New | +$55.6K | 0.01% | 447 |
|
|
2020
Q4 | $53K | Buy |
700
+200
| +40% | +$17.9K | 0.01% | 402 |
|
|
2020
Q3 | $53K | Hold |
500
| – | – | 0.01% | 371 |
|
|
2020
Q2 | $76K | Hold |
500
| – | – | 0.01% | 294 |
|
|
2020
Q1 | $42K | Hold |
500
| – | – | 0.01% | 373 |
|
|
2019
Q4 | $85K | Hold |
500
| – | – | 0.02% | 267 |
|
|
2019
Q3 | $93K | Hold |
500
| – | – | 0.03% | 251 |
|
|
2019
Q2 | $114K | Buy |
+500
| New | +$97.8K | 0.04% | 211 |
|
|
2018
Q4 | $58K | Hold |
500
| – | – | 0.02% | 253 |
|
|
2018
Q3 | $115K | Buy |
+500
| New | +$111K | 0.05% | 180 |
|
Other funds holding AXDX
Arax Advisory Partners's AXDX Position: Q2 2025 in Review
Arax Advisory Partners sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 1,000 shares — an estimated $701 sold.
Arax Advisory Partners first reported a position in AXDX in Q3 2018 and held it in 25 quarters. The position peaked at $115K in Q3 2018. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.
- Arax Advisory Partners reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
- Arax Advisory Partners sold 1,000 Accelerate Diagnostics shares in Q2 2025, an estimated $701.
- Arax Advisory Partners first reported a position in Accelerate Diagnostics in Q3 2018 and held it in 25 quarters.
- Arax Advisory Partners's Accelerate Diagnostics position peaked at $115K in Q3 2018.
- 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.
Based on Arax Advisory Partners's 13F filing for Q2 2025, filed 12 Aug 2025.